P J Cozzi1, R Englund, D L Morris. 1. University Department of Surgery, University of New South Wales, St. George Hospital, Sydney, Australia.
Abstract
BACKGROUND: Liver metastases from neuroendocrine tumors often present with disabling symptoms due to syndromes of hormonal excess. A locally destructive technique such as hepatic cryotherapy not only alleviates symptoms but may improve survival in this group of patients. METHODS: Six patients with metastatic neuroendocrine tumors were treated with hepatic cryotherapy. Four patients were symptomatic and three of these had elevated tumor markers from ectopic hormone production. RESULTS: All patients are alive and asymptomatic, with a median follow-up of 24 months (range, 6 months to 6 years). All have had a complete radiologic response. All with elevated preoperative markers have had a greater than 89% decrease in tumor markers. Coagulopathy occurred in two patients necessitating additional surgery, but there was no other morbidity attributable to the cryotherapy. CONCLUSION: To the authors' knowledge, this study demonstrates for the first time that hepatic cryotherapy offers supportive treatment for patients with neuroendocrine tumors metastatic to the liver. Cryotherapy alleviates symptoms and may improve survival.
BACKGROUND: Liver metastases from neuroendocrine tumors often present with disabling symptoms due to syndromes of hormonal excess. A locally destructive technique such as hepatic cryotherapy not only alleviates symptoms but may improve survival in this group of patients. METHODS: Six patients with metastatic neuroendocrine tumors were treated with hepatic cryotherapy. Four patients were symptomatic and three of these had elevated tumor markers from ectopic hormone production. RESULTS: All patients are alive and asymptomatic, with a median follow-up of 24 months (range, 6 months to 6 years). All have had a complete radiologic response. All with elevated preoperative markers have had a greater than 89% decrease in tumor markers. Coagulopathy occurred in two patients necessitating additional surgery, but there was no other morbidity attributable to the cryotherapy. CONCLUSION: To the authors' knowledge, this study demonstrates for the first time that hepatic cryotherapy offers supportive treatment for patients with neuroendocrine tumors metastatic to the liver. Cryotherapy alleviates symptoms and may improve survival.
Authors: Sean C Glasgow; Sathyabama Kanakasabai; Sabarinathan Ramachandran; T Mohanakumar; William C Chapman Journal: J Gastrointest Surg Date: 2006-03 Impact factor: 3.452
Authors: John G Touzios; James M Kiely; Susan C Pitt; William S Rilling; Edward J Quebbeman; Stuart D Wilson; Henry A Pitt Journal: Ann Surg Date: 2005-05 Impact factor: 12.969
Authors: Ruxanna T Sadikot; L James Wudel; Duco E Jansen; Jacob P Debelak; Fiona E Yull; John W Christman; Timothy S Blackwell; William C Chapman Journal: J Gastrointest Surg Date: 2002 Mar-Apr Impact factor: 3.452
Authors: Alexander F Hagel; Wolfgang H Hagel; Annette S Lindner; Ferdinand J Kammerer; Markus F Neurath; Peter C Konturek; Igor A Harsch Journal: Med Sci Monit Date: 2011-08